A controversial new law that introduces biosimilar substitution in Germany is due to come into force in the next few weeks. The provisions will likely lead to tendering, which would be the wrong approach to increasing biosimilar penetration, according to Alexander Natz, secretary general of EUCOPE, the European Confederation of Pharmaceutical Entrepreneurs.
The Act for Greater Security in the Pharmaceutical Supply System, known locally as GSAV, passed through both houses of parliament,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?